Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05681741
Other study ID # Ramsay Sante Sauvegarde Clinic
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2023
Est. completion date September 12, 2023

Study information

Verified date September 2023
Source Clinique de la Sauvegarde
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cerebral autoregulation is defined by the capacity of the brain to maintain a constant cerebral blood flow (CBF) despite variations of arterial pressure. However, when the arterial pressure is below a critical threshold, cerebral blood decreases. This critical threshold is called the lower limit of cerebral autoregulation (LLA). Cardiopulmonary bypass is a unique environment wherein systemic blood flow is totally controlled by the cardiopulmonary bypass pump. High pump flows combined with low arterial pressures has been shown to not compromise neurologic postoperative outcomes. Our hypothesis is that that LLA may depend on the cardiopulmonary bypass flow, ie the LLA may decrease when the cardiopulmonary bypass flow increases, explaining why low arterial pressure may be well tolerated.


Description:

Cerebral tissue perfusion is partly ensured by cardiac output and arterial pressure. In cardiac surgery, and especially during bypass surgery, one of the main objectives is to maintain sufficient blood flow and an optimal mean arterial pressure (MAP) to limit the deleterious consequences of organ hypoperfusion. To have a physiological regional organ blood flow, some organs, such as the brain, need a minimum MAP threshold (the lower limit of autoregulation, LLA) to ensure a constant cerebral blood flow (CBF). This is known as the cerebral autoregulation (CA). As the brain is at high risk of ischemia and definitive functional consequences in case of cerebral hypoperfusion, maintaining MAP above the LLA of the brain limit the deleterious postoperative neurological outcome. CA can be determined by continuously calculating the correlation between MAP and CBF. CBF is assessed by continuous monitoring of the middle cerebral artery velocity (mV). moving Pearson correlation coefficient between 30 consecutive, paired MAP and cerebral blood flow velocity values will be calculated to generate the mean velocity index (Mx). The Blood pressure in the autoregulation range is indicated by an Mx value that approaches zero (there is no correlation between flow velocity and MAP), whereas an Mx approaching 1 indicates dysregulated cerebral blood flow (flow velocity and MAP are correlated). A value of 0.4 is accepted as the threshold of CA corresponding to the LLA. During cardiopulmonary bypass (CPB), MAP is physiologically related to bypass flow and systemic vascular resistance. The adjustment of MAP during CPB is therefore achieved by the administration of vasoconstrictors or vasodilators as well as by the variations of the pump flow. This research assumes that a change in the pump flow rate will lead to a change in the LLA. Therefore, if the flow rate is higher, it is possible that the LLA will be lower. In this randomized trial, two different rates of pump flow will be compared with respect to LLA testing. Regional brain oxygen saturation, assessed by near-infrared spectroscopy will also be monitored during surgery.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 12, 2023
Est. primary completion date July 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patient, male or female, over the age of 18 - Patient scheduled to undergo valvular heart surgery with planned CPB - Patient with a Euroscore below 7% - Patient affiliated or entitled to a social security scheme - Patient having received informed information about the study and having signed a free and informed consent to participate in the study Exclusion Criteria: - Patient with untreated or uncontrolled severe hypertension despite treatment - Patient with chronic renal failure, with glomerular filtration < 30 mL/min/1.73m² or requiring a kidney transplant - Patient with left ventricular ejection fraction < 40% - Patient with a history of ischemic stroke - Patient having or about to benefit from renal vascular surgery - Patient with preoperative sepsis - Patient who required a norepinephrine infusion within 24 hours before surgery - Patient presenting with an inaccessible temporal Doppler window - Patient candidate for emergency surgery - Pregnant, parturient or breastfeeding woman - Patient with preoperative uni or bilateral carotid stenosis > 50% - Protected patient: adult under guardianship, curators or other legal protection, deprived of liberty by judicial or administrative decision

Study Design


Intervention

Procedure:
current versus high pump flow
during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors

Locations

Country Name City State
France Clinique de la Sauvegarde Lyon

Sponsors (2)

Lead Sponsor Collaborator
Clinique de la Sauvegarde GCS Ramsay Santé pour l'Enseignement et la Recherche

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary measurement of MAP LLA (mmHg) Determination of MAP LLA according to the calculation of the mean velocity index 15 to 25 min during the procedure
See also
  Status Clinical Trial Phase
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Completed NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass N/A
Recruiting NCT01231776 - Acupuncture Improves Sleep in Patients Undergoing Cardiopulmonary Bypass N/A
Completed NCT00747331 - Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass Phase 4
Terminated NCT00176657 - The Use of HEMOBAG to Salvage Blood After Cardiac Surgery Phase 2
Completed NCT00161733 - Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery Phase 3
Completed NCT05525195 - Influence of Preop Fibrinogen on Blood in Pediatric Cardiac Surgery
Completed NCT05537168 - Bayesian Networks in Pediatric Cardiac Surgery
Completed NCT04238806 - Desflurane,Brain Natriuretic Peptide and Cardiac Surgery N/A
Completed NCT00981474 - Cerebral Autoregulation Monitoring During Cardiac Surgery N/A
Recruiting NCT05588011 - Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass N/A
Completed NCT02566733 - Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass Phase 4
Terminated NCT00385450 - Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor Phase 1
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Not yet recruiting NCT05075265 - Pharmacokinetics of Methadone in Adults Undergoing Cardiac Surgery With Extracorporeal Circulation
Recruiting NCT04296071 - Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
Completed NCT05579964 - The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot Phase 2/Phase 3
Active, not recruiting NCT04133740 - Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study Phase 4
Completed NCT05033236 - Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)